32
Participants
Start Date
October 11, 2017
Primary Completion Date
November 6, 2019
Study Completion Date
December 31, 2021
Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
Molecular Screening
Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo
Istituto Nazionale Tumori - IRCCS, Milan
Istituto Oncologico Veneto - IRCCS, Padua
Grande Ospedale Metropolitano Niguarda, Milan
Fondazione del Piemonte per l'Oncologia
OTHER